Results 1 to 10 of about 172,168 (267)
Some of the next articles are maybe not open access.

A Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.

Journal of Medicinal Chemistry, 2020
The BCR-ABL fusion oncoprotein causes CML or some ALL in Ph+ patients because the ABL kinase is constitutively activated. However, current clinical treatment with ABL inhibitors is seriously limited by the drug resistance and adverse effects.
Yiqing Yang   +6 more
semanticscholar   +1 more source

Recent advances in Bcr‐Abl tyrosine kinase inhibitors for overriding T315I mutation

Chemical Biology and Drug Design, 2020
BCR‐ABL is a gene produced by the fusion of the bcr gene and the c‐abl proto‐oncogene and is considered to be the main cause of chronic myelogenous leukemia (CML) production.
Juan Liu   +6 more
semanticscholar   +1 more source

Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.

Journal of Medicinal Chemistry, 2019
The oncogenic fusion protein BCR-ABL is the driving force of leukemogenesis in chronic myeloid leukemia (CML). Despite great progress for CML treatment through application of tyrosine kinase inhibitors (TKIs) against BCR-ABL, long-term drug ...
Quan-Ju Zhao   +14 more
semanticscholar   +1 more source

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Science, 2001
M. Gorre   +6 more
semanticscholar   +1 more source

Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells

Oncogene, 2020
N. Shibata   +7 more
semanticscholar   +1 more source

Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand.

Bioorganic & Medicinal Chemistry Letters, 2016
Y. Demizu   +8 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy